Valirx (VAL)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 3.30p
   
  • Change Today:
      0.000p
  • 52 Week High: 14.13
  • 52 Week Low: 3.30
  • Currency: UK Pounds
  • Shares Issued: 132.35m
  • Volume: 0
  • Market Cap: £4.37m
  • RiskGrade: 435

ShareCast News

ValiRx raises ?0.2m through placing with new inv... 01-Apr-2020 ShareCast
ValiRx signs letter of intent in a bid to fund V... 14-Jan-2020 ShareCast
ValiRx granted US patent for 'VAL201' compound 28-Nov-2019 ShareCast
ValiRx allowed European patent on 'VAL301' compo... 01-Aug-2019 ShareCast
ValiRx to work with Aptus on VAL301 clinical dev... 04-Jul-2019 ShareCast
ValiRx gets US patent protection for use of VAL2... 26-Jun-2019 ShareCast
ValiRx secures \'substantial amendment\' to VAL2... 20-Jun-2019 ShareCast
ValiRx losses widen as it continues to progress ... 29-May-2019 ShareCast
ValiRx acquires IP of failed firm FIT Biotech, f... 02-May-2019 ShareCast
ValiRx shares surge as ValiSeek joint venture ma... 26-Mar-2019 ShareCast
ValiRx allowed patents for VAL401 in Russia and ... 31-Jan-2019 ShareCast
ValiRx gives NHS Long Term Plan its seal of appr... 09-Jan-2019 ShareCast
VAL401 results accepted for journal publication,... 18-Dec-2018 ShareCast
ValiRx releases positive data from recent VAL201... 10-Dec-2018 ShareCast
ValiRx enters finals stages of clinical trials o... 17-Oct-2018 ShareCast
ValiRx enters 'very exciting' phase for cancer t... 06-Sep-2018 ShareCast
ValiRx awarded US patent for endometriosis treat... 17-Jul-2018 ShareCast
ValiRx rockets on 'increased confidence' in lung... 14-Jun-2018 ShareCast
ValiRx granted crucial EU patent for VAL201 25-Apr-2018 ShareCast
ValiRx soars on anti-cancer compound's successfu... 19-Apr-2018 ShareCast
ValiRx narrows losses after cutting R&D costs 10-Apr-2018 ShareCast
ValiRx gets US patent for VAL201 compound 20-Mar-2018 ShareCast
ValiRX awarded regulatory approval to fast track... 18-Dec-2017 ShareCast
ValiRx losses widen as it continues drug develop... 05-May-2017 ShareCast
ValiRx's shares rise after VAL401 cancer-drug tr... 08-Mar-2017 ShareCast
ValiRx raises £1.16m in placing 01-Mar-2017 ShareCast
ValiRx upbeat on positive VAL201 study results 11-Jan-2017 ShareCast
ValiRx reports good progress at Georgia drug trial 03-Nov-2016 ShareCast
ValiRx updates market on 'significant' 2015 19-May-2016 ShareCast
ValiRx achieves success in latest VAL201 trial 16-Feb-2016 ShareCast
ValiRx confident in two ongoing clinical trials 09-Feb-2016 ShareCast
Valirx's lung cancer treatment receives positive... 02-Sep-2014 ShareCast
Tuesday broker round-up UPDATE 10-Jun-2014 ShareCast
ValiRX reports encouraging progress despite losses 05-Sep-2013 ShareCast
ValiRx granted patent in Australia for VAL201 ta... 25-Apr-2013 ShareCast
ValiRx to present at key Cancer Conference 02-Apr-2013 ShareCast
ValiRx appoints COO to help build portfolio 21-Feb-2013 ShareCast
Small cap round-up: InterQuest, ValiRx, Aeorema ... 22-Nov-2012 ShareCast
Contract wins round-up: LO-Q, Motive TV, Plexus ... 11-Oct-2012 ShareCast
Small cap round-up: ValiRx, Transense, Sweett 29-May-2012 ShareCast
Small caps round-up: Cello, DDD, Kewill... 15-May-2012 ShareCast
Small caps round-up: James Cropper, ValiRx, ReNe... 27-Apr-2012 ShareCast
Small caps round-up: Rock Solid, ValiRx, Interne... 02-Apr-2012 ShareCast
Small caps round-up: Caza, Tower Resources, Nove... 02-Feb-2012 ShareCast
Valirx wins Canadian patent for 'gene-silencing'... 15-Dec-2011 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Valirx Market Data

Currency UK Pounds
Share Price 3.30p
Change Today 0.000p
% Change 0.00 %
52 Week High 14.13
52 Week Low 3.30
Volume 0
Shares Issued 132.35m
Market Cap £4.37m
RiskGrade 435

Valirx Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
18.92% below the market average18.92% below the market average18.92% below the market average18.92% below the market average18.92% below the market average
13.21% above the sector average13.21% above the sector average13.21% above the sector average13.21% above the sector average13.21% above the sector average
Price Trend
93.92% below the market average93.92% below the market average93.92% below the market average93.92% below the market average93.92% below the market average
85.96% below the sector average85.96% below the sector average85.96% below the sector average85.96% below the sector average85.96% below the sector average
Income Not Available
Growth Not Available

Valirx Dividends

No dividends found

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

Valirx Key Personnel

CFO Gerald Desler
CEO Suzanne Dilly

Top of Page